David M. Jablons

20.7k citations
274 papers · 14.3k · 1 hit paper · h-index 62

Impact in

  • Oncology top 0.5%
    • Lung Cancer Research Studies
    • Lung Cancer Treatments and Mutations
    • Occupational and environmental lung diseases
    • Lung Cancer Diagnosis and Treatment
    • Pleural and Pulmonary Diseases

Papers in

    • Wnt/β-catenin signaling in development and cancer 39
    • Cancer-related gene regulation 35
    • Epigenetics and DNA Methylation 26
    • Lung Cancer Treatments and Mutations 36
    • Lung Cancer Diagnosis and Treatment 33
    • Occupational and environmental lung diseases 26

David M. Jablons

270 papers receiving 14.0k citations

David M. Jablons's Hit Papers

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer 2004 · 1.5k citations
1.5k0+7+14Years since publication50010001.5k

Peers

David M. Jablons
Comparison fields: 5 of 142
  • Oncology 3.9k
  • Pulmonary and Respiratory Medicine 4.4k
  • Cancer Research 1.7k
  • Molecular Biology 6.2k
  • Immunology 1.4k
Replace Wolter J. Mooi with:
Wolter J. Mooi Netherlands
Lee J. Helman United States
Dan Theodorescu United States
Élisabeth Brambilla France
Yoshitaka Sekido Japan
Ronald Simon Germany
Christopher J. Logothetis United States
David Raben United States
Timothy C. Thompson United States
Sheung Tat Fan Hong Kong
David M. Jablons relative to Wolter J. Mooi Netherlands Wolter J. Mooi's profile →
Citations per field
00.5×1.5×1.9×
Wolter J. Mooi · 1×
Citations per year

Countries citing papers authored by David M. Jablons

Since Specialization
Citations

This map shows the geographic impact of David M. Jablons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Jablons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Jablons more than expected).

Fields of papers citing papers by David M. Jablons

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Jablons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Jablons. The network helps show where David M. Jablons may publish in the future.

Co-authors

The 25 scholars most cited alongside David M. Jablons, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David M. Jablons Line = papers co-authored together David M. Jablons links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 274 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Hit paper breakdown →
20041517
2 2005381
3 2003312
4 2005280
5 2003272
6 2016263
7 2008257
8 2014247
9
Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia.
1992240
10 2007229
11 2004228
12 2004221
13 2004218
14 2005207
15 1990196
16 2007189
17 2005189
18 2007188
19
Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway.
2002184
20 2004183

About David M. Jablons

David M. Jablons is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Oncology, Cancer Research and Immunology, having authored 274 papers that have together received 14.3k indexed citations. Recurring topics across this work include Wnt/β-catenin signaling in development and cancer (39 papers), Lung Cancer Treatments and Mutations (36 papers), Cancer-related gene regulation (35 papers), Lung Cancer Diagnosis and Treatment (33 papers), Epigenetics and DNA Methylation (26 papers), Occupational and environmental lung diseases (26 papers), Cancer Research and Treatments (17 papers) and Cancer Cells and Metastasis (16 papers). The work is most often cited by research in Oncology (3.9k citations), Pulmonary and Respiratory Medicine (4.4k citations), Cancer Research (1.7k citations), Molecular Biology (6.2k citations) and Immunology (1.4k citations). David M. Jablons has collaborated with scholars based in United States, China and Taiwan. Frequent co-authors include Liang You, Zhidong Xu, Biao He, Frank McCormick, Kazutsugu Uematsu, Julien Mazières, Amie Y. Lee, Iwao Mikami, Cheng‐Ta Yang and John Nemunaitis. Their work appears in journals such as Journal of Thoracic Oncology, Clinical Lung Cancer, Oncotarget, Oncogene and Journal of Thoracic and Cardiovascular Surgery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact